Efficacy and Safety of Brolucizumab for Diabetic Macular Edema

阿柏西普 医学 糖尿病性视网膜病变 视力 随机对照试验 眼科 临床终点 黄斑水肿 糖尿病 外科 贝伐单抗 化疗 内分泌学
作者
Rishi P. Singh,Mark Barakat,Michael S. Ip,Charles C. Wykoff,David Eichenbaum,Sunir Joshi,David Warrow,Veeral Sheth,Jana Štefaničková,Yong‐Soo Kim,Fanyin He,Han Joo Cho,Yuhua Wang,Andrés Emanuelli
出处
期刊:JAMA Ophthalmology [American Medical Association]
卷期号:141 (12): 1152-1152 被引量:17
标识
DOI:10.1001/jamaophthalmol.2023.5248
摘要

Despite the effectiveness of existing anti-vascular endothelial growth factor (VEGF) therapies, a need remains for further treatment options to improve response rates and/or reduce injection or monitoring frequency in patients with diabetic macular edema (DME).To evaluate the efficacy and safety of brolucizumab vs aflibercept dosed every 4 weeks in participants with DME.This 52-week, double-masked, phase 3 randomized clinical trial included treatment-naive adults and adults who had previously received anti-VEGF therapy. Data were collected from September 2019 to March 2020, and data were analyzed from April 2020 to February 2021.Brolucizumab, 6 mg, intravitreal injection every 4 weeks or aflibercept, 2 mg, intravitreal injection every 4 weeks.Participants were randomized 2:1 to brolucizumab, 6 mg, or aflibercept, 2 mg. The primary end point was change from baseline in best-corrected visual acuity at week 52. Secondary end points were the proportion of participants with a 2-step improvement or greater from baseline in Diabetic Retinopathy Severity Scale score, the proportion of eyes with absence of both subretinal fluid and intraretinal fluid, change from baseline in central subfield thickness, and safety at week 52.A total of 517 participants were randomized to brolucizumab (n = 346) or aflibercept (n = 171); 299 (57.8%) were male, and the mean (SD) age was 60.7 (10.2) years. Brolucizumab was noninferior to aflibercept in best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study letter score) change from baseline at week 52 (brolucizumab, 12.2-letter improvement; aflibercept, 11.0-letter improvement; difference, 1.1; 95% CI, -0.6 to 2.9; noninferiority margin, 4; P < .001). Brolucizumab was superior to aflibercept for the proportion of eyes without subretinal and intraretinal fluid (brolucizumab, 144 of 346 [41.6%]; aflibercept, 38 of 171 [22.2%]; difference, 20.0%; 95% CI, 12.5to 28.6; P < .001) and mean central subfield thickness change from baseline at week 52 (brolucizumab, -237.8 μm; aflibercept, -196.5 μm; difference, -41.4; 95% CI, -58.9 to -23.8; P < .001). Incidence of intraocular inflammation was 4.0% (14 of 346) in the brolucizumab arm and 2.9% (5 of 171) in the aflibercept arm, incidence of retinal vasculitis was 0.9% (3 of 346) and 0.6% (1 of 171), respectively, and incidence of retinal vascular occlusion was 0.3% (1 of 346) and 0.6% (1 of 171). One participant in the brolucizumab arm had retinal artery occlusion.In these study participants with DME, no clinically meaningful differences in visual outcomes were noted between the brolucizumab and aflibercept arms; some superior anatomic improvements were noted in the brolucizumab arm. No new safety concerns were identified.ClinicalTrials.gov Identifier: NCT03917472.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_Z30GJ8发布了新的文献求助30
刚刚
syvshc的应助被ke采纳,获得10
刚刚
刚刚
脑洞疼的应助被martin采纳,获得30
2秒前
哈呼呼发布了新的文献求助30
3秒前
GIN的应助被zww采纳,获得10
3秒前
粟兮兮完成签到,获得积分10
3秒前
TT发布了新的文献求助10
4秒前
Akim的应助被tongtong采纳,获得10
4秒前
柠檬味电子对儿完成签到,获得积分10
4秒前
情怀的应助被lunhui6453采纳,获得10
4秒前
4秒前
烟花的应助被不散的和弦采纳,获得10
5秒前
ni完成签到,获得积分10
5秒前
莫晓岚完成签到,获得积分10
6秒前
今后的应助被匆匆采纳,获得10
7秒前
研友_VZG7GZ的应助被wuzhi采纳,获得10
7秒前
太渊发布了新的文献求助10
8秒前
哈猪的妈发布了新的文献求助10
9秒前
menyu的应助被淡淡的新筠采纳,获得10
9秒前
脑洞疼的应助被TT采纳,获得10
10秒前
Nole的应助被5Enu采纳,获得10
10秒前
10秒前
二硫碘化钾完成签到,获得积分20
11秒前
李爱国的应助被SuperGai采纳,获得10
12秒前
SJD完成签到,获得积分0
13秒前
14秒前
kali发布了新的文献求助200
15秒前
flash完成签到,获得积分10
16秒前
tongtong发布了新的文献求助10
16秒前
完美世界的应助被贝奇采纳,获得10
16秒前
xiaolizi发布了新的文献求助10
16秒前
大个的应助被weilanhaian采纳,获得10
16秒前
17秒前
三文鱼发布了新的文献求助10
17秒前
17秒前
18秒前
18秒前
科研通AI6.3的应助被匆匆采纳,获得10
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192519
求助须知:如何正确求助?哪些是违规求助? 9579028
关于积分的说明 21863207
捐赠科研通 7792025
什么是DOI,文献DOI怎么找? 3436955
关于科研通互助平台的介绍 2560622
邀请新用户注册赠送积分活动 2483832